JP Morgan Chase
RLAY icon

JP Morgan Chase’s Relay Therapeutics RLAY Stock Holding History

JP Morgan Chase’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,000
Closed -$99K – 7269
2023
Q1 		$99K Buy
+6,000
New +$108K ﹤0.01% 5437

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

JP Morgan Chase's RLAY Position: Q1 2026 in Review

JP Morgan Chase increased its Relay Therapeutics (RLAY) stake by 52% in Q1 2026, buying an estimated $1.98M and bringing the position to 647,518 shares worth $6.05M. The position accounts for ﹤0.01% of the portfolio, ranked #3140.

JP Morgan Chase first reported a position in RLAY in Q3 2020 and has held it in 23 quarters since. The position peaked at $112M in Q3 2022. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • JP Morgan Chase held 647,518 shares of Relay Therapeutics worth $6.05M as of Q1 2026.
  • JP Morgan Chase bought 221,560 Relay Therapeutics shares in Q1 2026, an estimated $1.98M.
  • Relay Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3140 holding.
  • JP Morgan Chase first reported a position in Relay Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • JP Morgan Chase's Relay Therapeutics position peaked at $112M in Q3 2022.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.